ABSTRACT
IMPORTANCE Despite years of investigation and billions of dollars, there is no cure or even a disease-slowing remedy for Alzheimer’s disease (AD). Most studies thus far have focused on amyloid beta plaques (Aβ) and neurofibrillary tangles as therapeutic targets, and only a few on modulating the associated inflammatory process.
OBJECTIVE To determine if exposure to Bacillus Calmette–Guérin (BCG) during treatment of non-muscle-invasive bladder cancer (NMIBC) is associated with a lower risk of developing AD.
DESIGN, SETTING AND PARTICIPANTS Multicenter retrospective study of 12,185 bladder cancer patients including 2301 BCG-treated patients between 2000 and 2019 meeting all inclusion criteria. Data was retrieved from two tertiary hospital systems in Israel and the United States, and the largest Israeli health provider database, with a median follow up of 3.5 to 7 years.
MAIN OUTCOMES AND MEASURES The primary outcome was time to the first occurrence of AD/Dementia events following a diagnosis of bladder cancer by trans-urethral resection (TURBT) in BCG treated patients, and in bladder cancer patients not receiving BCG (control group).
RESULTS BCG treatment was associated with a significantly reduced risk of developing AD in bladder cancer patients of ≥75 years following BCG treatment. A competing risk model using Cox Proportional-Hazard (PH) analysis applied to the largest medical records data showed a Hazard Ratio (HR) of 0.726 (95% CI: 0.529 – 0.996, P = 0.0473). The results were duplicated in analyzing NMIBC patients from a tertiary hospital with a HR of 0.416 (95% CI: 0.203 – 0.853, P = 0.017). A reduction in the risk (by 28%) for developing Parkinson’s disease (PD) was also shown in bladder cancer patients subjected to BCG immunotherapy.
CONCLUSIONS AND RELEVANCE BCG treatment for bladder cancer patients was associated with a significantly reduced risk for developing AD and PD in the elderly population (>75 years), and in NMIBC patients from a tertiary hospital. Prospective studies in elderly inoculated with intradermic BCG should be initiated to evaluate the potential protective effect of BCG against AD and PD.
Question Whether bladder cancer patients treated with BCG immunotherapy have a lower risk to develop AD than bladder cancer patients that do not receive such treatment.
Findings In a multicenter retrospective study composed of three cohorts covering >12,000 bladder cancer patients, those receiving intravesical BCG immunotherapy had a significantly lower risk of developing AD.
Meaning Intradermal inoculation of BCG to elderly people should be tested as a potential preventive approach against AD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Israel Science Foundation (ISF), grant 2753/20 (M.L). The Association for the War on Cancer in Israel, grant 20210066 (M.L.)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Helsinki approvals for this retrospective research on de-identified patients were obtained from the IRB of Clalit Health Services (CHS, #0160-19-COM), Hadassah University Hospitals (HUH, #0037-17-HMO) and UCLA Health System (UCLAH, DDR agreement of de-identified data repository).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
This is a cohort data all statistics are reported in the manuscript and in supplementary data.
